Synapse - Neha Korde

Search Within

Neha Sanat Korde

Results (226)

A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)

Meeting Abstract

Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
Blood (2020)

Fulltext@MSK | Save

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
Blood (2020)

Fulltext@MSK | Save

Association of patient activity bioprofiles with Hrqol and clinical responses: A prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients

Meeting Abstract

Korde, N.; Tavitian, E.; Derkach, A.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Lendvai, N.; Smith, E. L.; more...
Blood (2020)

Fulltext@MSK | Save

Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (-R): A phase 2 clinical and correlative study

Meeting Abstract

Kazandjian, D.; Hill, E.; Morrison, C.; Dew, A.; Korde, N.; Mailankody, S.; Manasanch, E. E.; Kwok, M. L.; Bhutani, M.; Tageja, N.; more...
Blood (2020)

Fulltext@MSK | Save

The role of (18)F-FDG-PET/CT in characterizing depth of response in high risk smoldering multiple myeloma patients treated with carfilzomib, lenalidomide, and dexamethasone (KRd)

Meeting Abstract

Hill, E.; Korde, N.; Morrison, C.; Dew, A.; Carpenter, A.; Epstein, M.; Lu, C.; Choyke, P.; Mena, E.; Lindenberg, L.; more...
Blood (2020)

Fulltext@MSK | Save

Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Meeting Abstract

Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
Blood (2020)

Fulltext@MSK | Save

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Review

Holstein, S. A.; Howard, A.; Avigan, D.; Bhutani, M.; Cohen, A. D.; Costa, L. J.; Dhodapkar, M. V.; Gay, F.; Gormley, N.; Green, D. J.; more...
Biology of Blood and Marrow Transplantation (2020)

Fulltext@MSK | Save

Stem cell mobilization and autograft minimal residual disease negativity with novel induction regimens in multiple myeloma

Journal Article

Bal, S.; Landau, H. J.; Shah, G. L.; Scordo, M.; Dahi, P.; Lahoud, O. B.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Lendvai, N.; more...
Biology of Blood and Marrow Transplantation (2020)

Fulltext@MSK | Save

Accelerated single cell seeding in relapsed multiple myeloma

Journal Article

Landau, H. J.; Yellapantula, V.; Diamond, B. T.; Rustad, E. H.; Maclachlan, K. H.; Gundem, G.; Medina-Martinez, J.; Arango Ossa, J.; Levine, M. F.; Zhou, Y.; more...
Nature Communications (2020)

Fulltext@MSK | Save

Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma

Journal Article

Eveillard, M.; Rustad, E.; Roshal, M.; Zhang, Y.; Ciardiello, A.; Korde, N.; Hultcrantz, M.; Lu, S.; Shah, U.; Hassoun, H.; more...
British Journal of Haematology (2020)

Fulltext@MSK | Save